Across TCGA pan-cancer cohorts, PRRT4 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated PRRT4 data layer compared with 23 for mass-spec protein.
The strongest signal is observed in colon adenocarcinoma (COAD), where higher PRRT4 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PRRT4 expression acts as an unfavorable survival marker.
COAD and READ are the cancer types where PRRT4 Mutation most reproducibly stratifies survival.